The Renal Project

Cover Block

Open sources

Name	The Renal Project
Tagline	Building a network of dialysis centers to expand access to kidney care in India.
Headquarters	Mumbai, India
Founded	2019
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology	No Technology Component
Geography	South Asia
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Pre-seed
Total Disclosed	~$1,330,000 (estimated) [CB Insights-style profile, January 2024]

Links

Open sources

• Website: https://www.cbinsights.com/company/the-renal-project
• LinkedIn: https://www.100x.vc/blog/interview-with-shashank-moddhia-the-renal-project-

What an Investor Needs First

Open sources

The Renal Project is building a network of dialysis centers to expand access to kidney care in India, a venture-scale bet on addressing a critical healthcare gap through physical infrastructure rather than software. Founded in 2019 by Shashank Moddhia after he left a quality assurance role at Baxter International, the company targets Tier II and III cities with a distributed model of micro-centers and home-based services [CB Insights-style profile, January 2024][100X.VC, 2026]. Its differentiation rests on operational execution in a capital-intensive, service-led model, promising affordability and accessibility where traditional healthcare networks are sparse.

Moddhia brings over 15 years of multinational experience in medical device quality assurance from Philips Healthcare and Baxter, a background that informs the company's adherence to ISO and Indian Society of Nephrology guidelines [100X.VC, 2026]. The venture is in its pre-seed phase, having secured an undisclosed investment led by the JITO Angel Network in January 2024, with participation from 100x VC and a syndicate of individual angels [CB Insights-style profile, January 2024]. Over the next 12-18 months, the key watchpoints are the pace of center rollout, the unit economics of its scalable 2-bed model, and its ability to secure the more substantial capital required to build a national network in a competitive landscape.

Partially corroborated -- Core company description and pre-seed round corroborated by a CB Insights-style profile; founder background and earlier funding referenced in an investor interview. Full capitalization and operational metrics are not publicly available.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	No Technology Component
Geography	South Asia
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Pre-seed (total disclosed ~$1,330,000)

Inside the Company

Open sources

The Renal Project was founded in 2019 by Shashank Moddhia, who left his role at medical device company Baxter International to launch the venture. The company is headquartered in Mumbai and operates as a dialysis services provider, a model shaped directly by Moddhia's background in quality assurance within the healthcare sector [CB Insights-style profile, January 2024][6].

Key operational milestones are anchored in its funding timeline and service model development. An initial pre-seed round of $299,000 was secured in August 2020, followed by a $370,000 seed round in July 2023 [2][4]. The company's most recent disclosed funding was a pre-seed investment led by the JITO Angel Network in January 2024, which included participation from 100x.VC and other angel investors [CB Insights-style profile, January 2024]. The capital has been directed toward building a network of dialysis centers, starting with a scalable model of centers with as few as two beds.

The founder's professional history is a consistent thread in the company's narrative. Shashank Moddhia is a biomedical engineering graduate and held quality assurance roles at Philips Healthcare and Baxter prior to founding The Renal Project [6][8]. The company states its operations adhere to the ISO 9001:2015 quality standard and guidelines from the Indian Society of Nephrology, a claim that aligns with the founder's stated 15 years of experience in quality systems.

Partially corroborated -- Founding details and funding rounds are cited, but some investor lists and operational specifics are aggregated from directory profiles.

Under the Hood

Reported and inferred

The Renal Project's core offering is a physical network of dialysis centers, a service-based model that addresses access through distributed infrastructure rather than a proprietary technology platform. The company operates dialysis centers and clinics, supplying the infrastructure and services required for hemodialysis [CB Insights-style profile, January 2024]. Its primary wedge is a lower-cost, distributed model designed to serve Tier II and Tier III cities in India, where access to renal care is limited [CB Insights-style profile, January 2024][3]. The model appears flexible, with centers described as scalable from a starting point of two beds upwards.

Beyond the core center-based service, the company has indicated a multi-pronged approach to care delivery. Public claims include providing home-based treatment solutions and operating a network of micro-centers alongside home dialysis services [6][10]. The company also states it offers ICU and emergency facilities at some locations, described as HHH+ and HHH- Centers. For clinical operations, the company claims its entire service delivery adheres to the ISO 9001:2015 Quality System Standard and guidelines set by the Indian Society of Nephrology.

A software component is mentioned but not detailed. The company claims to utilize in-house software for "world-class management" of its operations. A separate claim suggests the software allows nephrologists to access patient records with ease and security, potentially expanding the territory of patients a single doctor can manage. The technology stack is not publicly specified, and the depth of this software,whether it is a basic records system or a more integrated care coordination platform,remains unclear from available sources.

Partially corroborated -- Product claims are sourced from company profiles and directories; the software component and home-service scale are not independently corroborated.

Market Research

Open sources The addressable market for dialysis services in India is defined by a persistent and widening gap between clinical need and available infrastructure, a structural problem that has attracted both established operators and venture capital.

Third-party market sizing for India's dialysis sector specifically is not available in the public sources for this report. However, analogous data from adjacent markets and investor commentary frames the scale of the opportunity. The broader chronic kidney disease (CKD) treatment market in India, which dialysis services address, is substantial. For context, a major established player, NephroPlus, raised Rs 323 crore (approximately $40 million) in a Series D round from Bahrain's Investcorp, signaling institutional confidence in the category's growth potential [Times of India]. Another venture-backed competitor, VitusCare, was reported to be seeking over $10 million in a subsequent funding round after a $2.7 million Series A [VCCircle]. These capital influxes into direct competitors suggest investors see a sizable, underpenetrated market.

Demand is driven by a high and growing prevalence of end-stage renal disease (ESRD) in India, estimated in the millions, coupled with a severe shortage of dialysis centers, particularly outside major metropolitan areas. The company's stated focus on Tier II and III cities directly targets this geographic accessibility gap [CB Insights-style profile, January 2024]. A key tailwind is the increasing incidence of diabetes and hypertension, the primary causes of CKD, which expands the patient pool requiring renal replacement therapy over time. Furthermore, government insurance schemes and state-level health initiatives aimed at covering dialysis costs are gradually reducing the out-of-pocket burden for patients, potentially accelerating service adoption.

Key adjacent markets include home dialysis solutions and renal care management platforms, which represent both potential expansion vectors and competitive substitutes. For instance, iRen-MEDICAL offers a portable, digital dialysis solution for remote treatment [Calcalistech], while companies like Strive Health in the U.S. focus on value-based kidney care management. The regulatory environment is a defining force. Dialysis centers must adhere to strict guidelines from bodies like the Indian Society of Nephrology and maintain quality certifications such as ISO 9001:2015, which the company cites as a operational standard. Expansion speed is therefore contingent on navigating state-level healthcare regulations and securing necessary approvals for each new center.

NephroPlus Series D (2024) | 40 | $M
VitusCare Series A (2024) | 2.7 | $M
VitusCare Target Next Round | 10 | $M

The disclosed funding rounds for direct competitors provide a proxy for market validation and capital intensity, indicating that scaling a physical network requires significant investment, likely in the tens of millions of dollars.

Partially corroborated -- Market sizing is inferred from competitor funding rounds and general sector commentary; specific TAM/SAM for India's dialysis services is not confirmed by a third-party report.

Competition and Substitutes

Reported and inferred The Renal Project's competitive position is defined by its focus on asset-light, distributed dialysis infrastructure in underserved Indian markets, a model that sits between large-scale national chains and technology-focused device or software startups.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
The Renal Project	Network of micro-dialysis centers & home services in Tier II/III India	Pre-Seed (~$1.33M) [CB Insights, January 2024]	Asset-light, scalable 2-bed centers; targets accessibility gap	[CB Insights, January 2024]
NephroPlus	Large-scale dialysis service provider across India	Series D ($39M) [Times of India]	National footprint, established brand, institutional capital	[Times of India]
VitusCare	Dialysis center network backed by institutional VC	Series A ($2.7M) [VCCircle]	Expansion-focused, backed by Tomorrow Capital	[VCCircle]

The competitive map splits into three distinct segments. First, the incumbent service providers like NephroPlus, which have scaled through significant capital to build large, centralized centers, primarily in urban and semi-urban areas. Second, challenger networks like VitusCare and The Renal Project, which are also building physical footprints but with newer capital and a stated focus on expansion and accessibility. Third, a set of adjacent technology and device players, such as iRen-MEDICAL and X9, whose products could either substitute for or complement traditional center-based care by enabling home dialysis or improving clinical workflows.

Within the challenger segment, The Renal Project's stated edge is its operational model designed for lower-tier cities and its capital efficiency, with centers scalable from two beds. This approach targets a geographic and economic niche that may be less attractive to larger chains focused on higher-volume locations. The durability of this edge depends on executional discipline in site selection, local partnership management, and maintaining cost advantages as it scales. It is a perishable advantage if larger competitors decide to pursue a similar micro-center strategy or if operational complexity in distributed management erodes unit economics.

The company is most exposed on two fronts. It lacks the brand recognition and deep pockets of a scaled player like NephroPlus, which can use its size for procurement and payer negotiations. More critically, it operates in a service-heavy model with no proprietary technology barrier, making it vulnerable to competition from both other asset-light operators and, in the longer term, from home-based solutions like those from iRen-MEDICAL that could reduce the need for center visits altogether. The company does not own a proprietary device or a software platform that would be difficult to replicate.

A plausible 18-month scenario hinges on execution speed and capital. If The Renal Project can rapidly deploy its micro-center model and demonstrate strong unit economics and patient volumes in its target regions, it could establish a defensible regional footprint attractive for a strategic partnership or acquisition. The "winner" in this case would be a company like VitusCare if it secures its planned larger funding round and accelerates its own expansion, potentially outpacing The Renal Project. The "loser" would be any pure-service challenger that fails to achieve density and becomes a fragmented, sub-scale operator, struggling to compete on cost or convenience against both national chains and emerging home-care alternatives.

Partially corroborated -- Competitor profiles and funding are cited from public news reports, but direct comparative metrics (e.g., center counts, market share) for The Renal Project are not available.

Opportunity

Open sources The prize for The Renal Project is a national, asset-light network of dialysis centers that could capture a material share of India's underserved renal care market, a segment where demand chronically outpaces supply.

The headline opportunity is for The Renal Project to become a category-defining, distributed dialysis network in India, a position that would be defined by brand recognition, operational density, and partnership authority rather than proprietary technology. This outcome is reachable because the company's model directly targets the structural gap in India's healthcare infrastructure. The evidence points to a clear, unmet need: an estimated 200,000 new patients require dialysis each year in India, but the number of available centers remains insufficient, particularly in Tier II and III cities [Startup directory, 2024]. The Renal Project's wedge of building scalable, small-footprint centers starting from two beds directly addresses this bottleneck. Its early backing from a consortium of India-focused investors, including JITO Angel Network and 100x VC [CB Insights-style profile, January 2024], signals confidence in the execution of this asset-heavy but necessary service model.

Growth from a handful of centers to a national footprint would likely follow one of several concrete, high-scale paths. The company's public descriptions suggest a multi-pronged approach to expansion.

Scenario	What happens	Catalyst	Why it's plausible
Hub-and-Spoke Franchising	The company licenses its operational model and brand to independent clinic operators, rapidly scaling unit count without proportional capital outlay.	A successful pilot of 3-5 company-owned centers demonstrating unit economics and standardized protocols.	The model explicitly mentions operating centers with "scalable sizes starting from 2 beds and upwards" and collaborating with medical facilities to fill gaps [Startup directory, 2024], a natural precursor to a franchise system.
Hospital-Embedded Network	The Renal Project becomes the preferred third-party dialysis operator for mid-sized hospital chains, managing their renal care departments.	A landmark partnership with a regional hospital group to convert their dialysis unit.	The company's stated model involves collaborating "with medical facilities to 'fill the gap' where there is unavailability of dialysis centers" [Startup directory, 2024], indicating a B2B2C channel is already part of the strategy.
Integrated Home Care	The service portfolio expands to include a significant home dialysis segment, capturing higher-margin, recurring revenue from chronic patients.	Regulatory approval and insurance coverage for home-based dialysis solutions in India.	The company lists "home-based treatment solutions" and "home dialysis services" among its offerings [Startup directory, 2024], showing intent to move up the care continuum.

Compounding in this business looks less like a software flywheel and more like an operational and brand moat. Each new center increases local brand awareness, which drives patient volume and improves utilization rates for fixed-cost assets. Higher volume improves negotiating power with suppliers for dialysis consumables and equipment, directly improving unit economics. Furthermore, a growing network of centers generates proprietary data on patient outcomes and operational efficiency across diverse geographies, which can be used to refine protocols, attract better clinical talent, and potentially inform future technology or care model innovations. The founder's background in quality assurance systems for multinational healthcare firms suggests an early focus on standardizing these processes could accelerate this compounding effect [100X.VC, 2026].

To size the win, investors can look to a credible comparable: NephroPlus, a Hyderabad-based dialysis services provider. NephroPlus raised approximately $43 million (Rs 323 crore) in a Series D round from Investcorp [Times of India], validating the scale and investor appetite for a pan-Indian dialysis network. While NephroPlus is more mature, its existence and valuation provide a benchmark for what a scaled, branded dialysis chain can achieve in this market. If The Renal Project successfully executes on a hub-and-spoke or franchising scenario to reach a similar national footprint, it could plausibly command a valuation in the same high-tens to low-hundreds of millions of dollars range within a 5-7 year horizon (scenario, not a forecast). The total addressable market underpins this: with treatment costs ranging from $50-$100 per session and patients requiring multiple sessions weekly, the annual revenue potential per fully utilized center is significant, and capturing even a single-digit percentage of India's patient population represents a billion-dollar-plus service opportunity.

Partially corroborated -- Market sizing and growth scenario catalysts are inferred from company descriptions and a single comparable; the core opportunity framing is supported by multiple public profiles.

Sources

Open sources

1. [CB Insights-style profile, January 2024] The Renal Project | https://www.cbinsights.com/company/the-renal-project

2. [Startup directory, 2024] The Renal Project | https://www.18startup.com/company/the-renal-project

3. [100X.VC, 2026] Shashank Moddhia - Profile Interview | https://www.100x.vc/blog/interview-with-shashank-moddhia-the-renal-project-

4. [Times of India] NephroPlus raises Rs 323 crore from Bahrain's Investcorp | https://timesofindia.indiatimes.com/business/india-business/nephroplus-raises-rs-323-crore-from-bahrains-intercorp/articleshow/72231445.cms

5. [VCCircle] TomorrowCapital-backed dialysis firm VitusCare on road to raise fresh funds | https://www.vccircle.com/tomorrowcapital-backed-dialysis-firm-vituscare-on-road-to-raise-fresh-funds

6. [Calcalistech] iRen-MEDICAL | https://www.calcalistech.com/ctechnews/article/fu5a4tsrc